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LIST OF ABBREVIATIONS: 
AQP4= aquaporin-4, cR2= conditional R2, EDSS= expanded disability status scale, 
GCIPL= ganglion cell-inner plexiform layer, LETM= longitudinal extensive transverse 
myelitis, LGN=lateral geniculate nucleus, logMAR= logarithm of the minimum angle of 
resolution, mR2= marginal R2, MAGeT= Multiple Automatically Generated Templates, 
MRI= magnetic resonance imaging, NMO-NON: patients with NMOSD and no prior 
optic neuritis, NMO-ON: patients with NMOSD and prior optic neuritis, NMOSD= 
neuromyelitis optica spectrum disorders, ON= optic neuritis, OR= optic radiations, 
pRNFL= peripapillary retinal nerve fiber layer, SE= standard error, VPN= ventral 
posterior nucleus 
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ABSTRACT
OBJECTIVES: In neuromyelitis optica spectrum disorders (NMOSD) thalamic damage 
is controversial, but thalamic nuclei were never studied separately. We aimed at assessing 
volume loss of thalamic nuclei in NMOSD. We hypothesized that only specific nuclei are 
damaged, by attacks affecting structures from which they receive afferences: the lateral 
geniculate nucleus (LGN), due to optic neuritis (ON) and the ventral posterior nucleus 
(VPN), due to myelitis.
METHODS: Thirty-nine patients with aquaporin 4-IgG seropositive NMOSD 
(age:50.114.1 years, 36 women, 25 with prior ON, 36 with prior myelitis) and 37 
healthy controls (age:47.812 years, 32 women) were included in this cross-sectional 
study. Thalamic nuclei were assessed in magnetic resonance images, using a multi-atlas-
based approach of automated segmentation. Retinal optical coherence tomography was 
also performed. 
RESULTS: Patients with ON showed smaller LGN volumes (181.6±44.2 mm3) 
compared to controls (198.3±49.4 mm3; B=-16.97, p=0.004) and to patients without ON 
(206.1±50 mm3; B=-23.74, p=0.001). LGN volume was associated with number of ON 
episodes (Rho=-0.536, p<0.001), peripapillary retinal nerve fiber layer thickness 
(B=0.70, p<0.001) and visual function (B=-0.01, p<0.001). Although VPN was not 
smaller in patients with myelitis (674.367.5 mm3) than controls (679.768.33; B=-7.36, 
p=0.594), we found reduced volumes in five patients with combined myelitis and 
brainstem attacks (B=-76.18, p=0.017). Volumes of entire thalamus and other nuclei were 
not smaller in patients than controls. 
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CONCLUSION: These findings suggest attack-related anterograde degeneration rather 
than diffuse thalamic damage in NMOSD. They also support a potential role of LGN 
volume as an imaging marker of structural brain damage in these patients.
INTRODUCTION
Neuromyelitis optica spectrum disorders (NMOSD) are chronic, relapsing inflammatory 
disorders of the central nervous system, defined by pathogenic IgG antibodies against 
astrocytic aquaporin-4 (AQP4-IgG) in the majority of cases[1]. The most typical clinical 
manifestations are optic neuritis (ON) and acute myelitis, usually occurring as 
longitudinally extensive transverse myelitis[1,2]. Other clinical core characteristics 
include area postrema and acute brainstem syndromes[1].  
Patients with NMOSD very rarely show a secondary progressive phase[3], and the 
mechanisms leading to neurological disability are thought to be mainly attack-related[3–
5]. However, recent findings suggested retinal neuronal loss independent of ON attacks in 
NMOSD[6]. Moreover, some imaging[7,8] and histopathological studies in 
NMOSD[9,10] showed abnormalities and neuronal loss in non-lesional cortical grey 
matter. Less is known regarding deep grey matter changes in NMOSD, particularly the 
affection of the thalamus is controversial[11–16].
Our aim was to assess volume loss in thalamic nuclei in NMOSD. Our hypothesis was 
that lesions in i) the optic nerve due to ON and ii) the spinal cord due to myelitis may 
cause anterograde degeneration only to specific nuclei, with which these structures are 
connected. We hypothesized that the lateral geniculate nucleus (LGN), which receives 
afferences from the optic nerve, is affected due to ON and the ventral posterior nucleus 
(VPN), which receives afferences from the dorsal column-medial lemniscal pathway and 
the spinothalamic tract, due to myelitis (Fig. 1). Thus, we assessed LGN and VPN 
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volumes in NMOSD, and studied whether they are associated to clinical attacks (ON, 
myelitis), attack-related structural damage (in retina and spinal cord) and clinical deficits 
(visual and sensory dysfunction). Our secondary, exploratory objective was to investigate 
whether there is occult volume loss in other thalamic nuclei in NMOSD. 
METHODS
Study participants
We screened 78 patients with NMOSD from a prospective observational cohort study at 
the NeuroCure Clinical Research Center at the Charité-Universitätsmedizin Berlin 
(recruited from May 2013 to January 2018). The inclusion criteria were: i) age 18 years 
and ii) AQP4-IgG seropositive NMOSD, according to the 2015 International Consensus 
Diagnostic Criteria[1]. AQP4-IgG were determined by a cell-based assay (Euroimmun, 
Lübeck, Germany). Patients that were AQP4-IgG seronegative (n=25), had incomplete 
clinical data and/or unknown AQP4-IgG-status (n=10), no MRI data (n=3) or an attack 
within three months prior to baseline (n=1) were excluded. 
We included 39 AQP4-IgG seropositive NMOSD patients. Data from 37 healthy controls 
with age 18 years, without history of neurological or opthalmological diseases were also 
included. Helathy controls were chosen from the institute’s research database, to be as 
well matched as possible regarding age and sex to the patients. The characteristics of the 
study participants are presented in table 1.
Table 1: Characteristics of the NMOSD patients and controls included in the study
 
NMOSD Patients 
(n=39)
Controls (n=37)
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Aquaporin 4 IgG antibodies 
(seropositive, %)
39 (100%) -
Age, years (mean  SD) 50.1  14.1 47.8  12.5
Sex, female/male (female %)
36/3
(92.3%)
32/5
(86.5%)
Handedness (right/left) 34/4 33/2
Race (White/Black/Asian) 37/1/1 37/0/0
Disease duration, years (mean  SD) 8.8  8 -
Total number of previous attacks 
(median, range)
3 (1-22)
-
Patients with ON (n, %) 25 (64.1%) -
Number of ON episodes per patient 
(median, range)
1 (0-12) -
Time since fist ON episode, years 
(mean  SD)
9.6  7.5 -
Time since last ON episode, years 
(mean  SD)
5.4  3.7 -
Visual acuity, logMAR (mean  SD) 0.24  0.71 -0.01  0.22
pRNFL thickness, m (mean  SD) 79.1   21.2 96.0   9.2
GCIPL volume, mm3 (mean  SD) 1.6  0.3 1.9   0.2
Patients with myelitis (n, %) 36 (92.3%) -
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Number of myelitis episodes per 
patient  (median, range)
1 (0-15) -
Time since fist myelitis episode, 
years (mean  SD)
7.4  6.7 -
Time since last myelitis episode, 
years (mean  SD)
4.3  3.4 -
Patients with LETM in MRI at study 
baseline (n, %)
22 (56.4%) -
Sensory Functional System Score 
(median, range)
2 (0-4) -
Patients with brainstem attacks (n, %) 5 (12.8%) -
EDSS (median, range) 4 (0-7) -
Patients with other autoimmune 
diseases (n, %)
13 (33.3%) -
Patients on immunosuppressive 
treatment at study baseline (n, %)
34 (87.2%) -
Patients on daily corticosteroids at 
study baseline (n, %).
7 (17.9%) -
Note that there were 25 patients with previous ON; from them, 22 had both ON- and 
myelitis history, while 3 had only ON history, without myelitis. 
Visual acuity was tested monoocularly and thus the mean logMAR refers to the mean of 
both eyes. 
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The presence of LETM (defined as spinal cord lesions extending over at least 3 
vertebrae) was evaluated at study baseline, i.e. months or years after the myelitis 
episodes. 
Note that from the five patients that were not on immunosuppressive treatment at study 
baseline, only two were permanently untreated, due to severe leucopenia and long-term 
prednisone therapy, respectively. The other three were untreated at this time-point, due to 
side effects of previous treatments, but received immunosuppression later. Note also that 
seven patients were receiving daily oral steroids (prednisolone) at study baseline: one at a 
dose of 2mg/day, five at 5mg/day and one at 50mg/day. 
Abbreviations: EDSS= Expanded Disability Status Scale, LETM= longitudinal extensive 
transverse myelitis, logMAR= Logarithm of the Minimum Angle of Resolution, MRI= 
magnetic resonance imaging, NMOSD= neuromyelitis optica spectrum disorders, ON= 
optic neuritis, SD= standard deviation. 
This study was approved by the local ethics committee (Ethikkommission der Charité – 
Universitätsmedizin Berlin; EA1/131/09) and conducted in accordance with the 
declaration of Helsinki in its currently applicable version. All participants gave written 
informed consent before inclusion in the study.
Clinical assessment
Comprehensive neurological examinations were performed by raters, under supervision 
of board certified neurologists, to assess the Expanded Disability Status Scale (EDSS), 
including the functional system scores (FSS) according to the Neurostatus definitions. 
Attack history  was also recorded, using clinical criteria. 
Visual acuity was tested monocularly under photopic conditions using retroilluminated 
Early Treatment in Diabetes Retinopathy Study charts at a four-meter distance. The 
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logarithm of the minimum angle of resolution (logMAR) was used as a measure of visual 
function. We included the visual function measurement only from patients where best 
correction was used (n=30). 
Magnetic resonance imaging 
Magnetic resonance imaging (MRI) was performed for all participants at 3T 
(MAGNETOM Trio Siemens, Erlangen, Germany) on the same day as the clinical 
examination, except for two participants, where there was an interval of one day. Details 
regarding the MRI protocol and the assessment of thalamic- and optic radiation lesions 
are given as supplementary material. 
Measurement of thalamic volume and thalamic nuclei volume 
The volumes of the entire thalamus and the thalamic nuclei were measured using the 
Multiple Automatically Generated Templates (MAGeT) brain algorithm [17]on 3D T1-
weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) images. 
MAGeT uses an atlas derived from manually segmented serial histological data, 
including delineation of the thalamic nuclei. It first customizes the atlas to a subset of 
participants, representative of the study population, using nonlinear registration and uses 
this newly segmented subset as a template library for the remaining participants. This has 
the advantage of correcting for the neuroanatomical variability of the study population. 
Details regarding the representative subset of the present study are given as 
supplementary material. 
The segmentation results were visually inspected by one experienced rater (L.G.), who 
was blinded to the clinical data and no subjects had to be excluded. Last, all volumes 
were extracted and normalised using the SIENAX V-scaling factor for head-size[18]. 
Figure 1 and Supplementary figures 1 and 2 show examples of the LGN and VPN as 
segmented by MAGeT.  
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Mean upper cervical cord area
The mean upper cervical cord area (MUCCA) was used as a sensitive measure to assess 
spinal cord atrophy in patients with NMOSD[19]. Methodological details are given as 
supplementary material. 
Optical coherence tomography 
Retinal imaging was performed using a Heidelberg Engineering Spectralis spectral 
domain optical coherence tomography (OCT; Heidelberg Engineering, Heidelberg, 
Germany). We report the OCT acquisition settings, scanning protocol and details 
regarding excluded scans as supplementary material. 
The peripapillary retinal nerve fiber layer (pRNFL) thickness and the combined ganglion 
cell and inner plexiform layer (GCIPL) volume were used in the analysis. 
Statistical Analysis
Differences in age and sex-distribution between patients and controls were investigated 
using t-test and Fisher’s exact test, respectively. 
The associations of thalamic, LGN and VPN volumes with demographic characteristics 
were studied in controls using linear mixed effect models (LMM), with age, sex, 
handedness and brain side as fixed effects. If not stated otherwise, group comparisons, as 
well as structural-structural and structural-functional associations of thalamic nuclei were 
also performed using LMM, to account for intra-subject inter-side dependencies. Age and 
sex were always included as fixed effects in these models. The association of LGN 
volume with visual function was studied in LMM with monocular logMAR as dependent 
variable and LGN volume sum of both hemispheres as independent variable, since both 
LGN receive afferences from each eye. Relevant results were checked in additional 
LMM, adjusting for OR lesions and retinal damage (mean pRNFL thickness). We also 
performed analyses stratified for: i) ON (for LGN), ii) myelitis (for VPN), and iii) 
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brainstem attacks (for VPN). We report effect sizes from the LMM as marginal R2 (mR2), 
representing the variance explained by the fixed effects alone, and conditional R2 (cR2), 
representing the variance explained by both fixed and random effects. 
Associations between LGN and VPN volumes with number of attacks and FSS were 
studied through Spearman correlation tests, due to the non-normal distribution of these 
variables (analysis per patient, using the volume sum of both hemispheres). Bilateral ON 
was counted as two episodes. 
Last, we performed an exploratory analysis comparing all other thalamic nuclei between 
patients and controls, using LMM. This analysis was corrected for multiple comparisons 
using the Holm-Bonferroni method. 
For all models, statistical significance was achieved at p < 0.05. All statistical analysis 
was performed using R[20], version 3.4.3 with packages: pastecs, lme4, lmerTest, 
MuMIn and ggplot2. 
Data availability statement
All anonymised data not published within this article can be shared upon reasonable 
request from any qualified investigator. 
RESULTS
Demographics, clinical and imaging characteristics of the study population 
Patients with NMOSD and controls showed no difference regarding mean age (p=0.447), 
sex (p=0.475) or handedness (p=0.494; table 1). 
Twenty-five patients (64.1%) had a history of at least one ON (NMO-ON) and the rest 
never had an ON (NMO-NON). Most patients (92.3%) had at least one myelitis, while 
there were also five patients with a brainstem attack (table 1). 
A total of 17/39 (43.6%) patients had OR lesions, typically small, with nonspecific 
morphology (median lesion number: 0, range: 0-18). There was a single patient with a 
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left thalamic lesion. Since the left LGN and VPN volumes of this patient were not 
outliers (147.7 mm3 and 612.2 mm3, respectively) we did not exclude this patient from 
the analysis.
Volume of the entire thalamus 
In controls, thalamic volume was associated with age (B=-17.50, SE=8.45, p=0.047) and 
brain side, with the thalamus being larger on the right (7760.5 ± 602.3 mm3) compared to 
left (7185.7 ± 560.2 mm3; B=573.54, SE=34.26, p<0.001).
Total thalamic volume did not differ between NMOSD patients (7382.6  668.7 mm3) 
and controls (7473.1  646.1 mm3), when accounting for age and brain side (B=-68.49, 
SE=119.62, p=0.569).
Volume of the LGN
In controls, LGN volume was also associated with brain side, with the LGN being larger 
on the right (240.3  29.9 mm3) compared to left (156.3  20.6 mm3; B=83.42, SE=3.53, 
p<0.001), but not with age, sex or handedness. Mean LGN volume did not differ between 
NMOSD patients and controls (table 2). 
Table 2: Volumes of the lateral geniculate nucleus and ventral posterior nucleus in 
NMOSD patients and controls
 
Controls 
(n=37)
NMOSD 
(n=39)
NMO-
ON 
(n=25)
NMO-
NON 
(n=14)
NMOSD 
vs. 
controls
NMO-ON 
vs. 
controls
NMO-
NON vs. 
controls
LGN 
volume, 
mm3 
198.3 ± 
49.4
190.4 ± 
47.5
181.6 ± 
44.2
206.1 ± 
50
B= -9.38 
(SE=5.23)
p=0.077
B= -16.97 
(SE=5.65)
p=0.004
B= 5.31 
(SE=7.49)
p=0.483
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(mean  
SD)
Controls 
(n=37)
NMOSD 
(n=39)
NMOSD 
with 
myelitis 
(n=36)
NMOSD 
without 
myelitis 
(n=3)
NMOSD vs. 
controls
NMOSD with 
myelitis vs. 
controls
VPN 
volume, 
mm3 
(mean  
SD)
679.7  
68.3
676.5  
67.8
674.3  
67.5
703.2  
71.7
B= -4.58 
(SE=13.44) 
p=0.734
B= -7.36 
(SE=13.75) 
p=0.594
Legend: Note that due to the fact that there were only three NMOSD patients without 
myelitis, we did not compare VPN volume between patients with and without myelitis.  
Abbreviations: LGN= lateral geniculate nucleus, NMOSD= neuromyelitis optica 
spectrum disorders, NMO-ON= patients with NMOSD and previous optic neuritis, 
NMO-NON= patients with NMOSD and negative history of previous ON, SE= standard 
error, VPN= ventral posterior nucleus mm3
LGN volume was lower in NMO-ON patients compared to NMO-NON patients (B=-
23.74, SE= 6.76, p=0.001, mR2= 0.05, cR2=0.94; Fig. 2) and in NMO-ON patients vs. 
controls (table 2, Fig. 2). These results remained after exclusion of seven patients on daily 
prednisolone (data not shown). In contrast, there was no difference between NMO-NON 
patients and controls (table 2, Fig. 2).  
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For a separate analysis of the ipsi- and contralateral LGN volumes and their association 
to ON, see supplementary material. 
Volume of the LGN, optic neuritis and OCT parameters
In line with the smaller LGN found in NMO-ON, LGN volume inversely correlated with 
number of ON episodes in patients (Rho=-0.536, p<0.001; Fig. 2). When assuming a 
linear relationship, each ON episode led to, on average, an LGN volume loss of -3.09 
mm3 (SE=1.16, p=0.012). We did not find an association between LGN volume and time 
since first (B=-0.16, SE=0.67, p=0.809) or last ON episode (B= 1.28, SE= 1.29, p=0.33). 
In patients, LGN volume was associated with mean pRNFL thickness (B=0.70, SE=0.14, 
p<0.001, mR2=0.07, cR2=0.94) and mean GCIPL volume of both eyes (B=51.82, SE=11, 
p<0.001, mR2=0.06, cR2=0.94) (Fig. 2). The results were similar in models adjusted for 
OR lesions (pRNFL: B=0.71, SE=0.15, p<0.001; GCIPL: B=51.86, SE=11.10, p<0.001). 
In controls, there were no associations of pRNFL and GCIPL with LGN volume (data not 
shown). 
When looking at NMO-NON and NMO-ON patients separately, the associations of LGN 
volume with pRNFL thickness and GCIPL volume remained only in the NMO-ON 
subgroup (pRNFL: B=0.64, SE=0.21, p=0.007, mR2=0.05, cR2=0.93; GCIPL: B=40.18, 
SE=16.18, p=0.023, mR2=0.04, cR2=0.93), but not in NMO-NON patients (pRNFL: 
B=0.19, SE=0.55, p=0.741; GCIPL: B=40.51, SE=39.09, p=0.322). 
Volume of the LGN and lesions in the optic radiations 
Presence of OR lesions was not associated with ipsilateral LGN volume (B=-0.52, SE= 
6.35, p=0.935) and OR lesion number did not correlate with LGN volume (Rho=0.026, 
p=0.877). Moreover, LGN volume remained smaller in NMO-ON than in NMO-NON, 
when accounting for OR lesions (B=-23.74, SE= 6.82, p=0.001, mR2= 0.05, cR2=0.94).  
Volume of the LGN and visual function
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LGN volume (sum of both hemispheres) was associated with visual function measured as 
logMAR (B=-0.01, SE=0.002, p=0.002, mR2=0.22, cR2=0.27). This effect did not remain 
significant after inclusion of pRNFL thickness in the model (LGN: B=0.001, SE=0.002, 
p=0.613; pRNFL: B=-0.02, SE=0.003, p<0.001, mR2=0.52, cR2=0.52). 
Volume of the VPN
In controls, VPN volume was associated with brain side, with the VPN being larger on 
the left (706.7  65.8 mm3) compared to right (652.8  60.4 mm3; B=-54.44, SE= 6.54, 
p<0.001), but not with age, sex or handedness. 
Mean VPN volume was not different between NMOSD patients and controls (B=-4.58, 
SE=13.4, p=0.730; table 2 and Fig. 3). 
Volume of the VPN and myelitis 
There was no difference in VPN volume between patients with myelitis and controls 
(table 2). This remained after exclusion of seven patients on daily prednisolone (data not 
shown). Moreover, we found no correlation between VPN volume and number of 
myelitis episodes (Rho=-0.155, p=0.346; Fig. 3), time since first (B=-1.09, SE=1.48, 
p=0.466), or last myelitis (B=-4.32, SE= 2.78, p=0.131). 
To study associations between VPN and myelitis-related spinal cord damage, we used the 
mean upper cervical cord area (MUCCA; mean in patients: 68.3 ± 7.0 mm2 vs. 74.8 ± 6.4 
mm2 in controls). MUCCA was neither associated with VPN volume in NMOSD patients 
(B=-1.52, SE=1.33, p=0.261; Fig. 3) nor in the subgroup of patients with myelitis (B=-
2.45, SE=1.37, p=0.084). Similar results were seen in controls (data not shown). 
Moreover, there was no correlation between VPN volume and sensory FSS (Rho=-0.282, 
p=0.091). 
Volume of the VPN and brainstem attacks
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Due to the unexpected lack of association between VPN and myelitis, and since the VPN 
segmented in the present study included the ventral posterolateral nucleus, which receives 
afferences from the brainstem (trigeminothalamic tract), we performed a subgroup 
analysis in patients that had both myelitis and brainstem attacks (n=5; see table 3). 
Table 3:  Patients with myelitis and brainstem attacks
Pati
ent
First attack Further attacks 
before study-
baseline
Time since 
last 
brainstem 
attack
MRI at 
study-
baseline
1 Combined brainstem 
syndrome (double 
vision, nystagmus, 
tinnitus, headache, neck 
pain) and cervical 
myelitis (left 
hemiparesis) 
Six episodes of 
myelitis (incl. 
cervical myelitis), 
no further 
brainstem attacks
20.9 years
(last 
brainstem 
attack was 
the first 
attack)
LETM 
including the 
medulla and 
cervical 
spinal cord (to 
level C5)
2 Combined brainstem/ 
area postrema 
syndrome (double 
vision, nausea, 
vomiting, hiccups, 
dizziness) and cervical 
myelitis (sensory loss 
One further attack: 
combined 
brainstem 
syndrome 
(dizziness, double 
vision, nystagmus) 
and cervical 
myelitis (right 
3.66 years LETM 
including the 
medulla and 
cervical 
spinal cord (to 
level C6)
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and dysaesthesias on 
the left)
hemiparesis and 
hemiataxia) 
3 ombined cervical 
myelitis (paresthesias 
on the left hemibody 
and spastic tetraparesis) 
with brainstem 
syndrome („brainstem 
encephalitis“; no further 
details available) 
One further attack 
with 
nausea/vomiting 
and fatigue 
(probably 
brainstem/area 
postrema 
syndrome)
14.11 years Lesions in the 
medulla and 
in the cervical 
spinal cord 
(level C5)
4 Combined brainstem 
syndrome (dizziness, 
nystagmus, balance 
problems, headache and 
neck pain) and cervical 
myelitis (sensory loss in 
four extremities and 
trunk)
Five episodes of 
optic neuritis and 
two of myelitis, no 
further brainstem 
attacks
6.66 years 
(last 
brainstem 
attack was 
the first 
attack)
LETM 
including the 
medulla and 
cervical 
spinal cord (to 
level C7)
5 Brainstem 
syndrome/area 
postrema (double 
vision, nausea, 
vomiting, dizziness) 
One myelitis (one 
month after first 
attack), no further 
brainstem attacks
1.26 years 
(last 
brainstem 
attack was 
the first 
attack)
Multiple 
lesions in the 
medulla and 
cervical 
spinal cord, 
LETM in 
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thoracic 
spinal cord 
(Th4-10)
Legend: The lesions in the medulla and spinal cord of these patients were identified by 
two raters: a board-certified neurologist with experience in neuroimaging (A.P.) and a 
board-certified radiologist (M.S.), on sagittal T2-weighted spinal cord MR images 
(repetition time (TR) = 3500 ms, echo time (TE) = 101 ms, in-plane resolution = 0.91 
mm × 0.91 mm, slice thickness = 2 mm). Abbreviations: C= cervical, 
LETM=longitudinal extensive transverse myelitis, Th= thoracic
Indeed, we found lower VPN volumes in these patients (613.6  71.8 mm3) vs. controls 
(679.7  68.33; B=-76.18, SE=30.52, p=0.017, mR2=0.12, cR2=0.85; Fig. 4). Since two 
of these patients were on daily prednisolone, we also performed this analysis including 
prednisolone treatment as random effect and the result remained (B=-70.84, SE=31.83, 
p=0.048). There was also a correlation between VPN volume and number of brainstem 
attacks (Rho=-0.378, p=0.018), but no significant correlation with brainstem FSS (Rho=-
0.314, p=0.058). 
Volumes of the other thalamic nuclei
In an exploratory analysis, we investigated whether other thalamic nuclei were different 
in NMOSD patients vs. controls. Among nine nuclei, we found only the lateral posterior 
nucleus to be smaller in patients (table 4). When corrected for multiple comparisons, this 
effect became non-significant (corrected p=0.180).
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Table 4:  Volumes of the remaining thalamic nuclei in NMOSD patients and 
controls
Volume of 
thalamic nuclei
NMOSD Controls Comparison
Medial geniculate 
nucleus (mm3), 
mean ± SD
233.6 ± 34.1 233.2 ± 37.5
B=-0.49 (SE=5.18), 
p=0.925
Anterior nuclei 
(mm3), mean ± SD
177.9 ± 41.9 189.4 ± 45.1
B=-11.69 (SE=6.32), 
p=0.068
Central nuclei 
(mm3), mean ± SD
276.5 ± 60.2 273.1 ± 56.5
B=3.90 (SE=4.67),  
p=0.407
Lateral dorsal 
nucleus (mm3), 
mean ± SD
66.4 ± 13.8 66.6 ± 7.7
B=-0.25 (SE=2.05), 
p=0.903
Lateral posterior 
nucleus (mm3), 
mean ± SD
521.4 ± 77.2 547.0 ± 68.2
B=-27.1 (SE=11.34), 
p=0.020
Medial dorsal 
nucleus (mm3), 
mean ± SD
1129.2 ± 186.1 1131.2 ± 376.6
B=3.43 (SE=32.77), 
p=0.917
Pulvinar (mm3), 
mean ± SD
2022.0 ± 376.6 2028.4 ± 377.1
B=11.17 (SE=54.91), 
p=0.839
Ventral anterior 
nucleus (mm3), 
mean ± SD
647.7 ± 95.4 670.6 ± 111.2
B=-22.32 (SE=14.19), 
p=0.120
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Ventral lateral 
nucleus (mm3), 
mean ± SD
1007.2 ± 114.5 1022.4 ± 97.7
B=-13.93 (SE=16.92), 
p=0.413
Legend: Note that all volumes are normalised using the SIENAX V-scaling factor and 
that the p-values given are uncorrected for multiple comparisons. After correction for 
multiple comparisons, the lateral posterior nucleus was not smaller in NMOSD than 
controls (corrected p=0.180). Abbreviations: SE= standard error. 
DISCUSSION
In this study that assessed all thalamic nuclei in patients with NMOSD, we hypothesized 
that attack-related damage would be measurable as volume loss only in specific nuclei 
(LGN due to ON and VPN due to myelitis).
Indeed, LGN volume was reduced in NMOSD patients with ON history compared to 
controls, and also compared to patients without prior ON. Moreover, LGN volume was 
associated with number of ON episodes, retinal damage and visual function. These results 
strongly suggest anterograde degeneration in the afferent visual pathway of NMO-ON 
patients. Moreover, they support the use of LGN volume as an imaging marker of attack-
related brain structural damage in NMOSD, with also functional relevance. 
Anterograde degeneration in the visual pathway is well established in multiple sclerosis 
(MS) [21,22], while even in radiologically isolated syndrome there seems to be an 
association between retinal and thalamic volume loss[23]. In NMOSD, previous studies 
investigated transsynaptic degeneration in the visual pathway by analysing changes in the 
OR[15,24–27]. Several studies using diffusion tensor imaging [15,24,27,28] reported 
decreased OR fractional anisotropy, indicating microstructural OR-changes in NMO-ON 
patients vs. controls. A further study[25] showed reduced myelin water fraction, 
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suggesting reduced myelin density, in the OR of NMOSD patients (80% with prior ON) 
compared to controls. The interpretation of these findings was, that axonal loss in the 
optic nerve after ON can cause OR changes, by a propagation of damage through the 
LGN-synapses (anterograde transsynaptic degeneration). 
However, reported microstructural damage in the OR of NMOSD patients without prior 
ON [26,27]  suggests that white matter in this region might also be prone to direct 
changes due to NMOSD-related astrocytopathy. Thus, the specific assessment of the 
LGN, the grey matter structure where the actual synapses occur, is crucial to confirm 
transsynaptic degeneration and measure attack-related structural damage in the visual 
pathway in NMOSD. Moreover, LGN volume as assessed in our study has the advantage 
of using a broadly available MRI sequence (3D T1-weighted). This is important, since 
standardized diffusion tensor imaging for the OR-assessment is often hampered in 
clinical routine. 
The lack of data on LGN volume in NMOSD is probably due to the small LGN size, 
which makes its measurement technically challenging[22]. A single previous study[27] 
reported, in line with our results, reduced LGN volume in NMOSD patients with ON 
compared to controls and to patients without ON. In this previous study however, LGN 
volume was measured manually, which is prone to bias, especially for such a small 
structure[29]. In the present study, we used a multi-atlas-based tool of automated 
segmentation, the MAGeT Brain algorithm[17]. This algorithm is based on histological 
data, was validated against manual segmentations[30,31] and intraoperative 
recordings[31] and was previously used to investigate deep grey matter volume in 
patients with MS[29]. 
Next to this methodological strength, the present study included a –given the rarity of 
NMOSD in Europe[32]- relatively large (n=39) number of AQP4-IgG seropositive 
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NMOSD patients, compared to the heterogeneous population of Tian et al.[27], who 
analysed AQP4-IgG seropositive and seronegative patients together, and to the smaller 
sampler sizes of previous studies investigating the visual pathway of AQP4-IgG 
seropositive NMOSD[15,24–26].
Although previous work showed GCIPL volume reduction[6] and microstructural OR 
changes[26] in AQP4-IgG seropositive NMO-NON patients, our current results do not 
support a subclinical LGN volume loss in the absence of ON, since NMO-NON patients 
had normal LGN volumes. The reasons for this are not clear. It could be that 
neurodegenerative processes are different in the retina than the brain and in the white- 
than the grey matter in NMOSD. However, it cannot be ruled out that in this cross-
sectional study we had insufficient power to detect subtle subclinical volume loss at the 
LGN level.
The LGN volume was not associated with OR lesions in our study. This is in contrast to 
what was shown in MS[33], where findings suggest retrograde degeneration from OR 
lesions towards the retina[34]. The reason for this could be, that the typically small, 
nonspecific lesions observed in the OR of NMOSD patients are less destructive than 
demyelinating OR lesions in MS. This would be in line with the nonspecific morphology 
and asymptomatic nature of most white matter brain lesions in NMOSD[35–37]. 
In contrast to the LGN findings, VPN volume was not smaller in NMOSD patients with 
myelitis vs. controls and did not correlate with number of myelitis episodes. One possible 
explanation for these negative findings is, that compared to the small LGN, which 
receives afferences almost exclusively from the retina/optic nerve, the VPN is a larger 
nuclear complex receiving afferences from several regions [38]. Moreover, the VPN as 
segmented in the present study included not only the ventral posterolateral subnucleus 
(receiving afferences from the spinal cord), but also the ventral intermediate nucleus and 
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the ventral posteromedial subnucleus. The latter receives afferences from the 
trigeminothalamic tract in the brainstem[39]. Accordingly, we found reduced VPN 
volumes in five patients who suffered brainstem relapses. Four of these patients had 
attacks with brainstem or area postrema syndromes and cervical myelitis, with MRI 
lesions extending from the brainstem into the cervical spinal cord. We speculate that a 
lesion located in the most cranial part of the spinal cord (i.e. a shorter distance from the 
VPN) and the brainstem (i.e. close to the spinal tract of the trigeminal nerve and/or the 
trigeminothalamic tract) might be associated with the VPN volume loss seen in these 
patients. 
Another possible explanation for the lack of association between VPN and myelitis is the 
heterogeneous population of patients, with different degrees of sensory involvement, as 
well as spinal cord lesions with different lengths and locations. Last, it should be 
emphasized that lack of volume loss in the VPN does not necessarily mean lack of 
damage. Microstructural changes that do not necessarily result in a volume reduction or 
functional, adaptive changes could be present in the grey matter, despite “normal” 
volume. 
The volume of the entire thalamus was not reduced in our NMOSD patients compared to 
controls, which is in line with three previous European studies[13–15] with AQP4-IgG 
seropositive patients. However, three other Asian studies[11,12,16] reported reduced 
thalamic volumes compared to controls. In one of these studies[12], seven thalamic 
subregions (not corresponding to specific subnuclei) were also examined separately and 
almost all showed reduced volumes in NMOSD. These overall conflicting findings may 
be due to the genetically different NMOSD populations in Europe and Asia[40] and due 
to variability in antibody-status of the patients, with the Asian studies including also 10-
30% AQP4-IgG seronegative patients[11,12,16]. 
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A limitation of our study is the use of volume changes as the only measure of thalamic 
damage. Quantitative imaging methods, such as diffusion tensor imaging of thalamic 
nuclei, or even functional MRI might contribute to our understanding of microstructural 
and functional changes in NMOSD that do not necessarily result in volume loss, although 
their application in such small structures as the thalamic nuclei would be technically 
challenging. Moreover, the cross-sectional nature of the present study is a drawback. 
Longitudinal studies following changes in thalamic nuclei in patients with NMOSD after 
an acute (ideally the first) attack would be warranted in the future. 
To conclude, we found structural damage of the LGN due to ON in AQP-IgG 
seropositive NMOSD patients. Our results support the role of this thalamic nucleus as an 
imaging marker of attack-related neurodegenerative damage in the brain of these patients, 
also with functional relevance (association with visual function). Similar results were not 
observed for VPN and myelitis, although we saw an association with brainstem attacks, 
which needs confirmation in larger studies. Our findings suggest selective, attack-related 
rather than diffuse damage to thalamic nuclei in NMOSD. 
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FIGURE LEGENDS
Figure 1: Lateral geniculate and ventral posterior nuclei and their afferences in the 
visual and sensory pathways. 
A: The afferent visual pathway; note the LGN, which receives afferences from both optic 
nerves. We hypothesized LGN volume loss in NMOSD, due to optic neuritis. B: Axial 
T1-weighted 3D MPRAGE image showing an actual example of LGN segmentation (red) 
using the MAGeT brain algorithm in a control. Note also the optic tract in yellow. C: The 
thalamic VPN receives affereces from the spinothalamic pathway (in red) and dorsal 
column/medial lemniscal pathway (in green). We hypothesized VPN volume loss in 
NMOSD, due to myelitis involving these pathways. D: Coronal T1-weighted 3D 
MPRAGE image showing an actual example of VPN segmentation (turqoise) using the 
MAGeT brain algorithm in a control.  
The Schematic Figure of the Afferent Visual System (A) is adapted from the website of the 
Neurodiagnostics Laboratory @ Charité – Universitätsmedizin Berlin, Germany 
(http://neurodial.de/2017/08/25/schematic-figure-the-afferent-visual-system-creative-
commons-license).
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Figure 2: Volume of the lateral geniculate nucleus in NMOSD and its relationship 
with optic neuritis and retinal axonal damage. 
A: Normalized LGN volume per participant (mean of both hemispheres) in the three 
groups: controls in white, patients with NMOSD and negative ON history (NMO-NON) 
in light blue and patients with NMOSD and positive ON history (NMO-ON) in dark blue. 
B-C: Relationship between normalized LGN volume in NMOSD patients (sum of both 
hemispheres per patient) and: B) number of optic neuritis (ON) episodes, C) mean 
peripapillary retinal nerve fiber (pRNFL) thickness of both eyes. 
Figure 3: Volume of the ventral posterior nucleus in NMOSD and its relationship 
with myelitis and spinal cord damage.
A: Normalized volume of the ventral posterior nucleus (VPN; in mm3) per participant 
(mean of both hemispheres) in the three groups: controls in white, patients with NMOSD 
and myelitis in light blue and patients with NMOSD without myelitis in dark blue. No 
comparison was made between patients with- and without myelitis, due to the low 
number of the latter (n=3). B-C: Relationship between normalized VPN volume in 
NMOSD patients (sum of both hemispheres per patient) and: B) number of myelitis 
episodes, C) mean upper cervical cord area (MUCCA). 
Figure 4: Volume of the ventral posterior nucleus in patients with myelitis and 
brainstem involvement.
Normalized volume of the ventral posterior nucleus (VPN) per participant (mean of both 
hemispheres) in the groups: controls in white and patients with NMOSD, myelitis and 
brainstem relapses in light blue (“NMO-brainstem”). 
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Lateral geniculate and ventral posterior nuclei and their afferences in the visual and sensory pathways. 
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SUPPLEMENTARY MATERIAL 
METHODS 
Magnetic resonance imaging protocol 
Magnetic resonance imaging (MRI) was performed for all subjects at 3T (MAGNETOM Trio 
Siemens, Erlangen, Germany). The protocol included a 3D T1-weighted magnetization 
prepared rapid acquisition gradient echo (MPRAGE) sequence (repetition time (TR) =1900 
ms, echo time (TE) =3.03 ms, isotropic resolution 1x1x1 mm), and a 3D T2-weighted fluid-
attenuated inversion recovery (FLAIR) sequence (TR = 6000 ms, TE = 388 ms, isotropic 
resolution 1x1x1 mm) of the brain.  
Measurement of thalamic volume and thalamic nuclei volume using the MAGeT 
brain algorithm 
The Multiple Automatically Generated Templates (MAGeT) brain algorithm [1,2] was used 
to segment the entire thalami and the different thalamic nuclei on MPRAGE MR images.  
MAGeT uses an atlas derived from manually segmented serial histological data, containing 
delineation of the thalamic nuclei, as per Hirai and Jones [3]. It first customizes the atlas to a 
subset of participants, representative of the entire study population, using a nonlinear 
registration scheme.  
In our study, this representative subset was chosen in a manner consistent with best practices 
for the algorithm [4], according to age, sex and - for patients - number and type of attacks. It 
consisted of eleven NMOSD patients (ten women, mean age: 50±15.1 years, median number 
of attacks 3 (range 1-11), 10/11 with myelitis and 7/11 with ON) and ten controls (9 women, 
mean age: 47.4±12 years). This newly segmented subset acted as a template library for the 
remaining participants, to correct for the neuroanatomical variability of our study population 
and to average different sources of random error prior to the final segmentation [5]. 
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Lesions in the thalamus and the optic radiations  
The 3D T2-weighted fluid-attenuated inversion recovery (FLAIR) images of patients were 
assessed and verified for thalamic- and optic radiations (OR) lesions in consensus by a board-
certified neurologist (A.P.) and a board-certified radiologist (M.S.), to assess whether lesions 
in these strategic locations may influence our results.  
 
Mean upper cervical cord area 
The mean upper cervical cord area (MUCCA) was used as a sensitive measure to assess 
spinal cord atrophy in patients with NMOSD[6]. MUCCA was measured in 3D MPRAGE 
images using an active surface model[7] by averaging the cross-sectional areas from five 
consecutive slices at the C2/C3 intervertebral space level, as described previously[6,8].  
 
Optical coherence tomography: excluded scans and scanning protocol 
Retinal imaging was performed using a Heidelberg Engineering Spectralis spectral domain 
optical coherence tomography (OCT; Heidelberg Engineering, Heidelberg, Germany), with 
ART (automatic real-time) function for image averaging. We did not use pupil dilation. All 
patients had the OCT on the same day as the MRI and clinical examination, except for two, 
where there was an interval of one day. For the controls there was often an interval of few 
days between OCT and MRI/clinical assessment (on average: 7.4±11.7 days, range 0-50 
days). 
A total of ten eyes from eight patients had to be excluded from the analysis: six eyes due to 
incidental findings, three due to lack of OCT data, and one due to quality reasons, according 
to the OSCAR-IB criteria. For two additional eyes, only the macular scan had to be excluded, 
due to quality reasons[9]. 
The OCT acquisition settings and scanning protocol are reported below, according to the 
APOSTEL recommendations [10]:  
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The peripapillary retinal nerve fiber layer (pRNFL) was measured using 3.4-mm ring scans 
around the optic nerve head (12°, 1536 A-scans, 9≤ ART ≤100). The combined ganglion cell 
and inner plexiform layer (GCIPL) volume was measured using a 6-mm diameter cylinder 
around the fovea from a macular volume scan (25°x30°, 61 vertical B-scans, 768 A-scans per 
B-scan, ART=15). Segmentation of the pRNFL and the intraretinal layers in the macular scan 
was performed semi-automatically using software provided by the optical coherence 
tomography manufacturer (Eye Explorer 1.9.10.0 with viewing module 6.0.9.0; Heidelberg 
Engineering). All measurements were checked for segmentation errors and corrected if 
necessary, by one experienced rater (F.C.O.).  
 
RESULTS 
Volume of the LGN: differences between ipsilateral and contralateral side to 
optic neuritis (ON) 
Since the LGN of both hemispheres receive afferences from each optic nerve, both LGN 
were expected to be affected similarly after a unilateral ON episode.   
To confirm this, we performed an additional analysis comparing the LGN volume between 
patients with ON (NMO-ON) and without ON (NMO-NON) separately for unilateral LGN to 
ON and contralateral LGN to ON. From this analysis, 12 NMO-ON patients with bilateral 
ON were excluded. From the included NMO-ON patients (n=13), 6 patients had ON on the 
left eye and 7 patients on the right eye. The NMO-NON patients were 14.  
This analysis was performed using linear mixed effect models (LMM), with LGN volume 
being the dependent variable, ON history fixed effect, next to age and sex, and subject and 
side random effects. 
Although the volume of ipsilateral to ON LGN was smaller than the LGN volume of NMO-
NON patients (B=-21.10, SE= 8.69, p= 0.023, mR2= 0.05, cR2= 0.94), this was not the case 
for contralateral LGN to ON (B= -16.29, SE= 7.99, p= 0.052, mR2= 0.02, cR2=0.95). 
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However, the latter was a borderline not significant result, the p value being 0.052, and could 
be also due to the lower power of this subgroup analysis, which included a total of 41 LGN.   
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1: LGN segmentation by MAGeT 
 
Legend: The figure shows an example of the lateral geniculate nucleus (LGN) segmentation 
in a control subject, as performed by the MAGeT brain algorithm[1,2]. The LGN is shown in 
red at: A) axial, B) coronal and C) sagittal view, on a 3D T1-weighted magnetization 
prepared rapid acquisition gradient echo (MPRAGE) sequence.  
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Supplementary Figure 2: VPN Segmentation by MAGeT 
 
Legend: The figure shows an example of the ventral posterior nucleus (VPN) segmentation in 
a control subject, as performed by the MAGeT brain algorithm[1,2]. The VPN is shown in 
turquoise at: A) axial, B) coronal and C) sagittal view, on a 3D T1-weighted magnetization 
prepared rapid acquisition gradient echo (MPRAGE) sequence.  
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